biologic

symvess

acellular tissue engineered vessel-tyod

Loss of exclusivityDecember 2036FDA regulatory exclusivity expiry
CompanyHumacyte Global Inc.

Drug detail

Brand namesymvess
Active ingredientacellular tissue engineered vessel-tyod
Strength6 MM IN INNER DIAMETER,~42 CM LENGTH
Dosage formImplant
RouteImplantation
ModalityBiologic
FDA approvalDecember 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

symvess patent cliff — loss of exclusivity December 2036 | CliffBio